Human Insulin NPH and Insulin Aspart in Type 1 Diabetes

Comparative Evaluation of Human NPH Insulin + Insulin Aspart and Human NPH Insulin + Human Soluble Insulin in Type 1 Diabetes Mellitus

This trial is conducted in South America. This aim of this trial is to evaluate the comparative prandial blood glucose lowering profile in subjects with type 1 diabetes.

Inclusion Criteria:

• Type 1 diabetes for at least 12 months
• Treatment with insulin NPH
• Body Mass Index (BMI) below 30 kg/m2

Exclusion Criteria:

• Total daily insulin dose greater than 1.40 IU/kg
• Treatment with oral antidiabetic drugs (OADs)